Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02606084 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02606084 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 32 participants.
The verdict
NCT02606084, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetics of a single dose of intranasally administered esketamine in participants with impaired renal function when compared to participants with normal renal function.
Interventions
- DRUG Esketamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2015-12-04 |
| Est. Completion | 2018-02-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02606084
The ClinicalTrials.gov registry entry for NCT02606084 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Esketamine is the first listed.
NCT02606084 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02606084 about?
NCT02606084 is a clinical study titled "A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine". The purpose of this study is to evaluate the pharmacokinetics of a single dose of intranasally administered esketamine in participants with impaired renal function when compared to participants with normal renal function.
What is the current status of trial NCT02606084?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2015-12-04. Estimated completion is 2018-02-02.
What interventions are being tested in trial NCT02606084?
The interventions under investigation include: Esketamine (DRUG).
Who is sponsoring clinical trial NCT02606084?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.